NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria,…
Update on Regulatory Review of leriglitazone in the EU
A re-examination for cerebral adrenoleukodystrophy (cALD) will…
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Investigating potential for an oral treatment in diabetic…
Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease
Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper”…
Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
COPENHAGEN and SINGAPORE. Novo Holdings today announced its…
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
Synendos Therapeutics transitions to a clinical-stage biotech…
Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Market opportunity estimated to be greater than US$1 billion
Key…
AMSilk and 21st.BIO announce partnership to accelerate the production of advanced materials made from spider silk-based proteins
New protein production strain delivers unprecedented yield with…
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a…
Biocomposites expands its international presence by opening new sales and distribution office in Italy
Biocomposites SRL will support sales of STIMULAN, NanoBone,…
DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
New investment from DRW Venture Capital LLC and Tolmar International…
Futura Medical extends collaboration with Cooper Consumer Health
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…
Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
Berlin, Germany, 10th January 2024 – Ariceum Therapeutics,…
Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
COPENHAGEN, Denmark, Jan. 9, 2024 - The Novo Nordisk Foundation…
Futura Medical plc – Appointment of Roy Davis as Non-Executive Director
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York